跳转至内容
Merck
CN

Y0000714

利托那韦

European Pharmacopoeia (EP) Reference Standard

别名:

1,3-噻唑-5-基甲基 N-[(2S,3S,5S)-3-羟基-5-[[(2S)-3-甲基-2-[[甲基-[(2-丙-2-基-1,3-噻唑-4-基)甲基]氨基甲酰基]氨基]丁酰基]氨基]-1,6-二苯基己基-2-基]氨基甲酸酯

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C37H48N6O5S2
分子量:
720.94
UNSPSC代码:
41116107
NACRES:
NA.24

生物来源

synthetic

等级

pharmaceutical primary standard

Agency

EP

API类

ritonavir

包装

pkg of 80 mg

制造商/商品名称

EDQM

储存条件

protect from light

溶解性

ethanol: soluble
methanol: soluble

应用

pharmaceutical (small molecule)

格式

neat

运输

ambient

储存温度

2-8°C

InChI

1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

InChI key

NCDNCNXCDXHOMX-XGKFQTDJSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Ritonavir belongs to the group of protease inhibitors that are widely used in combination with other drugs in the prevention of HIV. Its mode of action involves binding to the active site of the protease enzyme and preventing the further maturation of new viral particles.

应用

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Mónica M Calderón et al.
Pharmacotherapy, 34(11), 1151-1158 (2014-08-22)
Panax ginseng has been shown in preclinical studies to modulate cytochrome P450 enzymes involved in the metabolism of HIV protease inhibitors. Therefore, the purpose of this study was to determine the influence of P. ginseng on the pharmacokinetics of the
Alicia Khululwa Khwitshana et al.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 104(7), 495-500 (2014-09-13)
HIV research is a therapeutic area for which well-defined population-specific treatment and prophylaxis guidelines exist. However, there are limited objective, evidence-based data for assessing adherence to these guidelines. To conduct a retrospective, cross sectional study of adult HIV-infected patients receiving
RP-HPLC method development and validation for simultaneous estimation of Lopinavir and Ritonavir in tablet dosage form
Bindu MJ, et al.
International Journal of Science and Engineering Applications, 5(1), 77-77 (2017)
HPTLC method for simultaneous determination of lopinavir and ritonavir in capsule dosage form
Sulebhavikar VA, et al.
Journal of Chemistry, 5(4), 706-712 (2008)
Kathleen Powis et al.
The Pediatric infectious disease journal, 33(11), 1141-1147 (2014-07-19)
Low maternal 25(OH)D (vitamin D) values have been associated with higher mortality and impaired growth among HIV-exposed uninfected (HEU) infants of antiretroviral (ART)-naive women. These associations have not been studied among HEU infants of women receiving ART. We performed a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门